2024-09-03 - Analysis Report
## AMGN Stock Analysis Report

**Company Overview:** Amgen Inc. (AMGN) is a leading biotechnology company focused on developing and delivering innovative therapies for patients with serious illnesses.

**Performance Analysis:**

**1.  Performance vs. S&P 500 (VOO):**

*   AMGN's cumulative return is 58.57%, while the S&P 500 (VOO) has generated a cumulative return of 89.66%.
*   The current deviation from the S&P 500 is -31.09%, meaning AMGN has underperformed the benchmark by approximately 31.09%.
*   The relative deviation of -31.09% corresponds to a position of 46.06% on the historical range of deviations (where 100% represents the maximum deviation). This suggests that AMGN's current underperformance is not an outlier compared to its historical performance against the S&P 500.

**2.  Recent Price Action:**

*   Closing price: 333.83
*   5-day moving average: 329.61
*   20-day moving average: 325.69
*   60-day moving average: 321.37

The recent price action indicates a positive short-term trend, with the closing price above all moving averages.

**3.  Technical Indicators:**

*   RSI (Relative Strength Index): 68.97, indicating a potentially overbought condition, but not in an extremely high range.
*   PPO (Price Oscillator): 0.17, suggesting positive momentum and potential for further upside.
*   Delta_Previous_Relative_Divergence: -12.38, a negative value suggesting a potential short-term bearish trend.
*   Expected_Return: 7.55%, representing the estimated maximum return over the next 5 years.

**4.  Recent Earnings and Outlook:**

| Date         | EPS   | Revenue  |
|--------------|-------|----------|
| 2024-08-07  | 1.39  | 8.39 B$ |
| 2024-05-03  | -0.21 | 7.45 B$ |
| 2023-10-31  | 3.23  | 6.90 B$ |
| 2023-08-04  | 2.58  | 6.99 B$ |
| 2024-08-07  | 2.58  | 6.99 B$ |

The most recent earnings report for Q2 2024 (released on 2024-08-07) showed an EPS of 1.39, beating analysts' estimates of 1.30. Revenue also surpassed expectations, reaching 8.39 billion dollars. This positive performance suggests a strong financial position for AMGN.

**5.  Summary:**

AMGN has underperformed the S&P 500 in the long term. However, recent price action indicates positive short-term momentum. Technical indicators point to potential overbought conditions, but also suggest positive momentum. The recent earnings report showcased strong performance and surpassed analysts' expectations. Overall, AMGN presents a mixed outlook, with positive short-term momentum but long-term underperformance compared to the market.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. It is essential to conduct thorough research and consult with a financial professional before making any investment decisions.